Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 153Melanoma 133Lymphoma 124Prostatic Neoplasms 123Carcinoma, Non-Small-Cell Lung 113Multiple Myeloma 106Carcinoma, Renal Cell 92Ovarian Neoplasms 88Leukemia, Myeloid, Acute 83Sarcoma 82Lung Neoplasms 80Leukemia, Lymphocytic, Chronic, B-Cell 80Leukemia 79Colorectal Neoplasms 79Colonic Neoplasms 74Rectal Neoplasms 71Lymphoma, Non-Hodgkin 69Pancreatic Neoplasms 68Carcinoma, Ovarian Epithelial 66Neoplasms 65Lymphoma, Large B-Cell, Diffuse 65Brain Neoplasms 65Precursor Cell Lymphoblastic Leukemia-Lymphoma 64Lymphoma, Follicular 58Kidney Neoplasms 58Glioblastoma 57Fallopian Tube Neoplasms 54Carcinoma, Hepatocellular 51Lymphoma, Mantle-Cell 50Central Nervous System Neoplasms 50

Interventions

Surgical Procedures, Operative 1Immunohistochemistry 1Erlotinib Hydrochloride 1Congresses as Topic 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × NIH × Pancreatic Intraductal Neoplasms × Clear all
NCT00482625 2014-10-16

Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Terminated
6 enrolled 8 charts
Gastrointestinal

Pancreatic Intraductal Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡